DAX22.978 -0,6%ESt505.444 -0,6%Top 10 Crypto12,57 +2,3%Dow42.588 ±0,0%Nas18.272 +0,5%Bitcoin81.474 +0,4%Euro1,0795 +0,1%Öl73,39 +0,3%Gold3.023 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Steyr Motors A40TC4 BYD A0M4W9 Bayer BAY001 HENSOLDT HAG000 Lufthansa 823212 DEUTZ 630500 Deutsche Bank 514000 thyssenkrupp 750000 Amazon 906866 Novo Nordisk A3EU6F Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX im Plus -- Asiens Börsen uneins -- GameStop überrascht beim Gewinn - Bitcoin wird zum Reservevermögen -- Porsche Holding mit Milliardenverlust -- RENK, Amazon im Fokus
Top News
SMI-Wert Sika-Aktie: Mit dieser Dividende bereitet Sika Aktionären eine Freude SMI-Wert Sika-Aktie: Mit dieser Dividende bereitet Sika Aktionären eine Freude
Stoxx Europe 50-Wert Roche-Aktie: Über diese Dividendenzahlung können sich Roche-Aktionäre freuen Stoxx Europe 50-Wert Roche-Aktie: Über diese Dividendenzahlung können sich Roche-Aktionäre freuen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
5 Quantencomputing-Aktien, die Wellen schlagen & es wert sind, für Ihr Portfolio in Betracht gezogen zu werden. Mehr erfahren!

Viatris Aktie

NeuKaufenVerkaufen
Viatris Aktien-Sparplan
8,39 EUR -0,12 EUR -1,41 %
XETRA
8,95 USD ±0,00 USD ±0,00 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.10,29 Mrd. EUR

Div. Rendite3,86%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2QAME

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS92556V1061

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVTRS

Viatris Aktien News

DatumMeistgelesen
PR NewswireViatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe M...
PR NewswireViatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
PR NewswireViatris to Participate in the Jefferies London Healthcare Conference
PR NewswireViatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
PR NewswireViatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
PR NewswireViatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance
PR NewswireViatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
PR NewswireRajiv Malik to Retire as President of Viatris Effective April 1, 2024
PR NewswireViatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
PR NewswireViatris to Release Third Quarter 2023 Financial Results on November 7, 2023
PR NewswireViatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
PR NewswireViatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Ago...
PR NewswireViatris Named to TIME's World's Best Companies 2023 List
MyDividendsViatris kündigt Dividende an
PR NewswireViatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
PR NewswireViatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstr...
PR NewswireVTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireVTRS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 14, 2023 in the Class Action Filed on Behalf of Viatris Inc. Shareholders
PR NewswireVIATRIS DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options
PR NewswireROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS
PR NewswireVTRS SHAREHOLDER ALERT: Jakubowitz Law Reminds Viatris Shareholders of a Lead Plaintiff Deadline of July 14, 2023
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRS
PR NewswireROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS
PR NewswireVTRS SHAREHOLDER ALERT: Jakubowitz Law Reminds Viatris Shareholders of a Lead Plaintiff Deadline of July 14, 2023
PR NewswireVTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireViatris to Report Second Quarter 2023 Financial Results on August 7, 2023
PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Viatris, Inc. and Certain Officers - VTRS
PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
PR NewswireVIATRIS INC. (NASDAQ: VTRS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Vi...
PR NewswireKESSLER TOPAZ MELTZER & CHECK, LLP ANNOUNCES A SECURITIES FRAUD CLASS ACTION FILED AGAINST VIATRIS INC. (VTRS)
PR NewswireViatris Named to USA Today's Inaugural List of America's Climate Leaders 2023
PR NewswireInvestor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Viatris Inc. (VTRS) Investors of Class Action and to Actively Participate
PR NewswireRobert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year
PR NewswireViatris Announces Appointment of Leo Groothuis to Company's Board of Directors
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
PR NewswireROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS
PR NewswireViatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
PR NewswireViatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine
Wer­bung

Viatris News

Viatris News: auf dieser Seite finden Sie alle Viatris News und Nachrichten zur Viatris Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Viatris News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Viatris News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.